AR048370A1 - COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY - Google Patents
COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORYInfo
- Publication number
- AR048370A1 AR048370A1 ARP040101363A ARP040101363A AR048370A1 AR 048370 A1 AR048370 A1 AR 048370A1 AR P040101363 A ARP040101363 A AR P040101363A AR P040101363 A ARP040101363 A AR P040101363A AR 048370 A1 AR048370 A1 AR 048370A1
- Authority
- AR
- Argentina
- Prior art keywords
- memory
- melatonin
- cognitive functions
- nicotine
- composition
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 3
- 229960003987 melatonin Drugs 0.000 abstract 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 206010022437 insomnia Diseases 0.000 abstract 2
- 229960002715 nicotine Drugs 0.000 abstract 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000002670 nicotine replacement therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Combinacion farmacologicamente activa de utilidad para el tratamiento de pacientes que padecen de insomnio, que incluye (a) al menos un primer ingrediente activo seleccionado de melatonina, otros agentes melatonérgicos, agonistas melatonina y antagonistas melatonina; y (b) al menos un segundo ingrediente activo seleccionado de agonistas de nicotina y de receptores de la nicotina. De un medicamento que incluye el componente (a) con o sin componente (b) para el alivio de al menos uno de los efectos adversos que ocurren en un paciente en el transcurso de la terapia de de sustitucion de la nicotina. Como desmejoramiento de la calidad del sueno, dificultades en las funciones cognitivas y de la memoria. Kit de utilidad en el tratamiento de pacientes que padecen de insomnio, que incluye los componentes (a) y (b) en la forma de unidad de dosis.Pharmacologically active combination useful for the treatment of patients suffering from insomnia, which includes (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least a second active ingredient selected from nicotine agonists and nicotine receptors. Of a medication that includes component (a) with or without component (b) for the relief of at least one of the adverse effects that occur in a patient during the course of nicotine replacement therapy. As a deterioration of the quality of sleep, difficulties in cognitive functions and memory. Kit useful in the treatment of patients suffering from insomnia, which includes components (a) and (b) in the form of unit dose.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL155666A IL155666A (en) | 2003-04-29 | 2003-04-29 | Composition for treating insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048370A1 true AR048370A1 (en) | 2006-04-26 |
Family
ID=33397641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101363A AR048370A1 (en) | 2003-04-29 | 2004-04-22 | COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8859593B2 (en) |
| EP (1) | EP1620058B1 (en) |
| JP (2) | JP4981440B2 (en) |
| KR (1) | KR101136885B1 (en) |
| CN (1) | CN1787820B (en) |
| AR (1) | AR048370A1 (en) |
| AT (1) | ATE539746T1 (en) |
| BR (1) | BRPI0409935A (en) |
| CA (1) | CA2521182C (en) |
| CL (1) | CL2004000877A1 (en) |
| CY (1) | CY1112689T1 (en) |
| DK (1) | DK1620058T3 (en) |
| EA (1) | EA008768B1 (en) |
| ES (1) | ES2380364T3 (en) |
| IL (1) | IL155666A (en) |
| IS (1) | IS8090A (en) |
| MX (1) | MXPA05011590A (en) |
| NO (1) | NO333015B1 (en) |
| NZ (1) | NZ542724A (en) |
| PE (1) | PE20050144A1 (en) |
| PL (1) | PL1620058T3 (en) |
| PT (1) | PT1620058E (en) |
| SI (1) | SI1620058T1 (en) |
| TW (1) | TWI340037B (en) |
| UA (1) | UA87980C2 (en) |
| UY (1) | UY28296A1 (en) |
| WO (1) | WO2004096118A2 (en) |
| ZA (1) | ZA200509508B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155666A (en) * | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
| JP4993900B2 (en) * | 2005-11-28 | 2012-08-08 | 国立大学法人 東京医科歯科大学 | Memory impairment inhibitor |
| US8372876B2 (en) * | 2007-03-06 | 2013-02-12 | The University Of Houston System | Method for improving memory in mammals |
| CA2682200C (en) | 2007-03-19 | 2015-01-13 | Vita Sciences, Llc | Transdermal patch and method for delivery of vitamin b12 |
| BRPI0811052A2 (en) | 2007-04-12 | 2015-01-27 | Univ Minnesota | ISCHEMIA / REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USE. |
| JP2015509106A (en) | 2012-01-26 | 2015-03-26 | ヴァンダ ファーマシューティカルズ インコーポレイテッ | Treatment of circadian rhythm disorders |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| KR102148990B1 (en) * | 2012-12-18 | 2020-08-27 | 반다 파마슈티칼즈, 인코퍼레이티드. | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| KR102361801B1 (en) * | 2015-02-04 | 2022-02-10 | 쏘 요세파 메넨데즈 | Transdermal therapeutic systems containing Valentonin and its use as a medicament |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| KR102499141B1 (en) * | 2016-10-31 | 2023-02-13 | 신신제약 주식회사 | Percutaneous absorption system for the treatment of sleep disorders |
| MX386987B (en) | 2016-10-31 | 2025-03-19 | Neurim Pharma 1991 | MELATONIN MINI-TABLETS AND METHODS OF MANUFACTURING SAME. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US468017A (en) * | 1892-02-02 | Lock-case | ||
| US4506080A (en) * | 1983-07-01 | 1985-03-19 | Nestec S. A. | Preparation of serotonine and derivatives |
| US4765985A (en) * | 1985-03-05 | 1988-08-23 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
| US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
| US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
| ES2028074T3 (en) | 1986-06-13 | 1992-07-01 | Alza Corporation | ACTIVATION BY MOISTURE OF A TRANSDERMIC PHARMACY SUPPLY SYSTEM. |
| DE3645036A1 (en) | 1986-11-18 | 1989-01-05 | Forschungsgesellschaft Rauchen | Nicotine-containing composition |
| MX9205981A (en) * | 1991-10-18 | 1993-04-01 | Alza Corp | TRANSDERMIC ADMINISTRATION OF MELATONIN. |
| WO1993014200A1 (en) * | 1992-01-07 | 1993-07-22 | Tsi Corporation | Transgenic animal models for alzheimer's disease |
| DE69303919T2 (en) * | 1992-04-07 | 1997-01-30 | Neurim Pharma 1991 | Use of melatonin in the manufacture of a medicament for the treatment of benign prostatic hyperplasia |
| US5449683A (en) * | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| JPH09505028A (en) * | 1993-07-09 | 1997-05-20 | シグナス，インコーポレイテッド | Methods and devices for providing percutaneous / buccal nicotine replacement therapy |
| JPH09512006A (en) * | 1994-04-13 | 1997-12-02 | チバ−ガイギー アクチェンゲゼルシャフト | Time-regulated drug delivery system |
| US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| JP4516159B2 (en) | 1995-02-01 | 2010-08-04 | ニューリム ファーマシューティカルズ（１９９１）リミテッド | Use of melatonin for the treatment of patients with drug addiction |
| US5696115A (en) | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
| US5700828A (en) * | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
| CZ298212B6 (en) | 1996-05-13 | 2007-07-25 | Novartis Consumer Health S. A. | Slowly erodible lozenge |
| FR2762993B1 (en) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | NEW USE OF PHOSPHOLIPIDS OF ANIMAL ORIGIN IN THERAPEUTICS AND / OR DIETETICS |
| ATE254618T1 (en) | 1997-05-30 | 2003-12-15 | Neurosearch As | SPIRO QUINUCLIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| US6274615B1 (en) * | 1998-03-25 | 2001-08-14 | South Alabama Medical Science Foundation | Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders |
| US6353015B1 (en) | 1998-08-26 | 2002-03-05 | St. Elizabeth's Medical Center | Method of treating neurodegenerative disorders |
| RU2134108C1 (en) | 1998-10-06 | 1999-08-10 | Заславская Рина Михайловна | Agent for treatment of patient with arterial hypertension, method of treatment of patient with arterial hypertension |
| FR2788982B1 (en) * | 1999-02-02 | 2002-08-02 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL |
| PL196413B1 (en) | 1999-02-05 | 2007-12-31 | Cipla Ltd | Topical sprays comprising a film forming composition |
| US6353051B1 (en) * | 1999-03-10 | 2002-03-05 | E. I. Du Pont De Nemours And Company | Top coating for synthetic leathers |
| HK1052655A1 (en) | 2000-01-05 | 2003-09-26 | 纽里姆药品(1991)有限公司 | Method and formulation for treating resistance to antihypertensives and related conditions |
| EP2140868A1 (en) * | 2000-03-03 | 2010-01-06 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy |
| DE10013712A1 (en) | 2000-03-20 | 2001-09-27 | Nutrinova Gmbh | Nicotine salts with improved taste, process for their preparation and their use |
| AU2001282873A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AR033444A1 (en) | 2001-03-26 | 2003-12-17 | Smithkline Beecham Corp | SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT |
| US7766013B2 (en) * | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| EP1304048B1 (en) | 2001-10-22 | 2004-09-22 | Ivo Pera | Composition to reduce or quit smoking addiction |
| US7113651B2 (en) * | 2002-11-20 | 2006-09-26 | Dmetrix, Inc. | Multi-spectral miniature microscope array |
| IL155666A (en) * | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
-
2003
- 2003-04-29 IL IL155666A patent/IL155666A/en active IP Right Grant
-
2004
- 2004-04-15 PL PL04727667T patent/PL1620058T3/en unknown
- 2004-04-15 EP EP04727667A patent/EP1620058B1/en not_active Expired - Lifetime
- 2004-04-15 BR BRPI0409935-4A patent/BRPI0409935A/en not_active Application Discontinuation
- 2004-04-15 CA CA2521182A patent/CA2521182C/en not_active Expired - Lifetime
- 2004-04-15 JP JP2006507610A patent/JP4981440B2/en not_active Expired - Lifetime
- 2004-04-15 MX MXPA05011590A patent/MXPA05011590A/en active IP Right Grant
- 2004-04-15 ES ES04727667T patent/ES2380364T3/en not_active Expired - Lifetime
- 2004-04-15 EA EA200501666A patent/EA008768B1/en unknown
- 2004-04-15 NZ NZ542724A patent/NZ542724A/en not_active IP Right Cessation
- 2004-04-15 CN CN2004800113428A patent/CN1787820B/en not_active Expired - Lifetime
- 2004-04-15 UA UAA200511154A patent/UA87980C2/en unknown
- 2004-04-15 WO PCT/IL2004/000330 patent/WO2004096118A2/en not_active Ceased
- 2004-04-15 AT AT04727667T patent/ATE539746T1/en active
- 2004-04-15 SI SI200431850T patent/SI1620058T1/en unknown
- 2004-04-15 US US10/555,011 patent/US8859593B2/en active Active
- 2004-04-15 KR KR1020057020416A patent/KR101136885B1/en not_active Expired - Lifetime
- 2004-04-15 PT PT04727667T patent/PT1620058E/en unknown
- 2004-04-15 DK DK04727667.0T patent/DK1620058T3/en active
- 2004-04-22 AR ARP040101363A patent/AR048370A1/en unknown
- 2004-04-26 CL CL200400877A patent/CL2004000877A1/en unknown
- 2004-04-28 TW TW093111816A patent/TWI340037B/en not_active IP Right Cessation
- 2004-04-28 PE PE2004000418A patent/PE20050144A1/en not_active Application Discontinuation
- 2004-04-29 UY UY28296A patent/UY28296A1/en not_active Application Discontinuation
-
2005
- 2005-10-25 IS IS8090A patent/IS8090A/en unknown
- 2005-11-23 NO NO20055531A patent/NO333015B1/en unknown
-
2006
- 2006-11-24 ZA ZA200509508A patent/ZA200509508B/en unknown
-
2012
- 2012-02-08 JP JP2012025361A patent/JP2012116859A/en active Pending
- 2012-04-02 CY CY20121100327T patent/CY1112689T1/en unknown
-
2014
- 2014-09-10 US US14/482,275 patent/US20140378512A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048370A1 (en) | COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY | |
| ATE454140T1 (en) | DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVES TO IMPROVE SLEEP QUALITY | |
| EA200600820A1 (en) | METHODS OF TREATMENT, MODIFICATION AND ELIMINATION OF PATIENTS USING 1-OXO-2- (2,6-DIOXOPYPERIDIN-3-IL) -4-METHYLISYNDOLINE | |
| CY1121330T1 (en) | COMPOSITIONS CONTAINING AZELASTIN AND METHODS OF USING THEM | |
| BRPI0507609A (en) | therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| AR060836A1 (en) | A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED | |
| DE60319967D1 (en) | METHOD FOR THE USE OF COMPOUNDS AND COMPOUNDS WITH IMMUNOMODULATIVE COMPOUNDS FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES | |
| CY1124763T1 (en) | METHOD FOR THE THERAPEUTIC TREATMENT OF PRIMARY INSOMNIA | |
| PT1173178E (en) | COMPOSITION UNDERSTANDING APOMORPHINE AND SILDENAFIL AND USES THEMSELVES FOR THE TREATMENT OF ERECTILE DISFUNCTION | |
| CO2018006358A2 (en) | Treatment of fabry disease in patients not treated and previously treated with ert | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| TW200616608A (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| UY29274A1 (en) | PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA | |
| CO2022016153A2 (en) | il4i1 inhibitors and methods of use | |
| CO6361995A2 (en) | ISOQUINOLINONE DERIVATIVES AS AN NG3 ANTAGONISTS | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| DE602006017728D1 (en) | CANCER TREATMENT BY AGENT AND 2-DEOXYGLUCOSE | |
| TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| BRPI0415651A (en) | methods for treating, preventing, modifying and / or administering fibromyalgia, and for reducing or preventing an adverse effect associated with the administration of a second active ingredient in a fibromyalgia patient, and, pharmaceutical composition. | |
| AR117861A1 (en) | CEREBROVASCULAR EVENT REDUCTION METHODS IN PATIENTS WITH FABRY'S DISEASE | |
| UY32353A (en) | TYPICAL OCULAR SOLUTIONS COMPOUNDS TO SUPPLY EFFECTIVE CONCENTRATIONS OF THE ACTIVE AGENT TO THE BACK EYE SEGMENT | |
| Mohamed et al. | Transdermal nitroglycerine as a coadjuvant to intrathecal nalbuphine with bupivacaine in lower abdominal surgery. | |
| AR046219A1 (en) | USE OF SELECTIVE MODULATORS OF OPERATIVE RECEPTORS IN THE TREATMENT OF NEUROPATHIES | |
| CO2025015643A2 (en) | Imidazotriazine derivatives as IL-17 modulators | |
| CA3249607A1 (en) | ANTI-INFECTIOUS AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |